The effect of isoflavonoid contents in SH003 and its subfractions on breast cancer

Yu-Jeong Choi; Won-Geun Choi; Kangwook Lee; Miso Jeong; Sang Cheol Park; Young Pyo Jang; Seong-Gyu Ko; Choi, Yu-Jeong; Choi, Won-Geun; Lee, Kangwook; Jeong, Miso; Park, Sang Cheol; Jang, Young Pyo; Ko, Seong-Gyu

doi:10.13048/jkm.22032

JKM > Volume 43(3); 2022 > Article

Choi, Choi, Lee, Jeong, Park, Jang, and Ko: The effect of isoflavonoid contents in SH003 and its subfractions on breast cancer

Original Article

The Journal of Korean Medicine 2022; 43(3): 79-93.

Published online: September 1, 2022

DOI: https://doi.org/10.13048/jkm.22032

The effect of isoflavonoid contents in SH003 and its subfractions on breast cancer

Yu-Jeong Choi¹^{, #}

, Won-Geun Choi¹^{, #}

, Kangwook Lee⁴

, Miso Jeong¹

, Sang Cheol Park²

, Young Pyo Jang³

, Seong-Gyu Ko⁴^{, *}

¹Department of Science in Korean Medicine, Graduate School, Kyung Hee University

²Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University

³Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee University

⁴Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University

Correspondence to: Seong-Gyu Ko, Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae Rd., Dongdaemun-gu, Seoul 02447, Korea, Tel: +82-2-961-0329, E-mail: epiko@khu.ac.kr

# These authors contributed equally to this work.

Received June 10, 2022 Revised July 8, 2022 Accepted August 16, 2022

Abstract

Objectives

We investigated the isoflavone contained in SH003 and its fractions, and the effect of these components on the inhibition of breast cancer.

Methods

The isoflavones in solvent fractions of SH003 extract were identified by UPLC-MS and its contents were quantified using HPLC analysis. The estrogenic activity of SH003 or fractions was assessed by ERE luciferase assay in estrogen receptor (ER)-positive MCF-7 cells. To test the breast cancer inhibitory effect, the cell viability was measured using an MTT assay.

Results

In this study, we demonstrated that SH003 and fractions contain 4 isoflavones which are calycosin-7-β -D-glucoside, formononetin-7-β-D-glucoside, calycosin, and formononetin. Despite containing isoflavones, estrogen-dependent transcription activity was not altered by both SH003 and fractions. On the other hand, SH003 and fractions inhibited the cell viability of breast cancer. In addition, its isoflavone components also showed reduced cell viability in various breast cancer cells.

Conclusions

Overall, the phytoestrogen included in SH003 and fractions did not influence the estrogenic activity, emphasizing the safety of SH003 and fractions in breast cancer treatment.

Keywords: SH003, fractions, isoflavone, phytoestrogen, anti-cancer effect, breast cancer

Acknowledgement

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2020R1A5A2019413).

Fig. 1

Scheme for preparation of fractions from SH003

Fig. 2

UPLC-MS chromatograms of SH003

(A) UPLC-MS TIC (top) and UPLC-UV (bottom) analysis. (B) The identification of major isoflavones. 1: calycosin 7-O-β-D-glucoside, 2: formononetin 7-O-β-D-glucoside, 3: calycosin, 4: formononetin.

Fig. 3

HPLC Standard curve of isoflavone

The standard curve was determined by peak areas calculated following the concentration (μg/mL) of the injected isoflavone standards.

Fig. 4

HPLC chromatograms of isoflavone standards and SH003 crude extract

(A) SH003 extract. (B) Isoflavone standards.

Fig. 5

A comparison of HPLC chromatograms between the batch number of SH003 extract

(A) SH003 Lot1. (B) SH003 Lot2. (C) SH003 Lot3.

Fig. 6

The analysis of ERE luciferase activity by SH003 and fractions

MCF-7 cells were transfected with ERE reporter plasmid for 24 h. Transfected cells were treated with SH003, fractions, and E2 for 24 h. Luciferase activity was measured using Fluoroskan FL Microplate Luminometer (ThermoScientific, USA). The Renilla luciferase is used to normalization.

Fig. 7

The effect of SH003 and fractions on breast cancer cell death

Breast cancer cells were treated with SH003 and fractions for 48h at indicated dose. The cell viability was detected by MTT assay. Data represent the mean ±SD. * P < 0.05. (A) ER+ breast cancer, (B) HER2+ breast cancer, (C) Triple-negative breast cancer (TNBC).

Fig. 8

The effect of isoflavone components on breast cancer cell death

Breast cancer cells were treated with 4 isoflavone for 48 h. The cell viability was measured by MTT assay. * P < 0.05.

Table 1

Extraction yield of SH003 fractions

	Lot	Powder (g)	Extraction yield (%)
H2O layer	1	177.4	88.7
	2	175.6	87.8
	3	165.1	82.55

n-Hexane layer	1	6.2	3.1
	2	6.2	3.1
	3	6.1	3.05

Chloroform layer	1	3.8	1.9
	2	3.26	1.63
	3	6.2	4.1

Ethyl acetate layer	1	1.68	0.84
	2	1	0.5
	3	0.25	0.13

Butanol layer	1	5.18	2.59
	2	3.47	1.74
	3	1.93	0.97

Table 2

The quantification of isoflavones in SH003 and SH003 fractions

Content (%)
Lot 1	SH003	Water	Butanol	Ethyl acetate	Chloroform	Hexane
Calycosin-7-O-β-D-glucoside	0.1	0.05	0.95	1.5	0.05	0
Formononetin-7-O-β-D-glucoside	0.04	0.01	0.29	1	0.09	0
Calycosin	0.05	0.01	0.18	0.45	0.62	0
Formononetin	0.06	0.01	0.11	0.18	0.46	0.09

Lot 2
Calycosin-7-O-β-D-glucoside	0.1	0.05	0.95	1.49	0.05	0
Formononetin-7-O-β-D-glucoside	0.04	0.01	0.3	1	0.09	0
Calycosin	0.06	0.01	0.18	0.47	0.63	0
Formononetin	0.07	0.01	0.12	0.2	0.53	0.09

Lot 3
Calycosin-7-O-β-D-glucoside	0.11	0.05	0.94	1.68	0.05	0
Formononetin-7-O-β-D-glucoside	0.04	0.01	0.29	1.06	0.09	0
Calycosin	0.05	0.01	0.18	0.46	0.62	0
Formononetin	0.06	0.01	0.11	0.18	0.51	0.1

MEAN+SD (%)	SH003	Water	Butanol	Ethyl acetate	Chloroform	Hexane
Calycosin-7-O-β-D-glucoside	0.10±0	0.05±0	0.95±0	1.56±0.05	0.05±0	0
Formononetin-7-O-β-D-glucoside	0.04±0	0.01±0	0.29±0	1.02±0.02	0.09±0	0
Calycosin	0.05±0	0.01±0	0.18±0	0.46±0	0.62±0	0
Formononetin	0.06±0	0.01±0	0.11±0	0.19±0	0.5±0.02	0.09±0

참고문헌

1. Li, S., et alAnti-tumor effects and mechanisms of Astragalus membranaceus (AM) and its specific immunopotentiation: Status and prospect. J Ethnopharmacol. 258:11279710.1016/j.jep.2020.1127972020.

2. Zhang J., et alAnti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds. Anticancer Agents Med Chem. 12:1239–1254. 10.2174/1871520128038330712012.

3. Zhang J., et alFormononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells. J Ethnopharmacol. 221:91–99. 10.1016/j.jep.2018.04.0142018.

4. Kweon, B., et alEffect of Angelica gigas Nakai Ethanol Extract and Decursin on Human Pancreatic Cancer Cells. Molecules. 25:10.3390/molecules250920282020.

5. Minh C.V., et alChemical constituents of Trichosanthes kirilowii and their cytotoxic activities. Arch Pharm Res. 38:1443–1448. 10.1007/s12272-014-0490-62015.

6. Choi Y.J., et alSH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med. 16:50710.1186/s12906-016-1490-52016.

7. Choi Y.K., et alHerbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm. 2014:49217310.1155/2014/4921732014.

8. Kim T.W., Cheon C., Ko S.G.SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells. Cell Death Dis. 11:71710.1038/s41419-020-02924-w2020.

9. Jeong M.S., et alSynergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer. Int J Mol Sci. 2210.3390/ijms221684052021.

10. Han N.R., et alThe immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) or its active constituent nodakenin. J Ethnopharmacol. 285:11489310.1016/j.jep.2021.1148932022.

11. Lee K., et al Herbal Prescription SH003 Alleviates Docetaxel-Induced Neuropathic Pain in C57BL/6 Mice. Evid Based Complement Alternat Med. 2021:412033410.1155/2021/41203342021.

12. Lumachi F., Brunello A., Maruzzo M., Basso U., Basso S.M.Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 20:596–604. 10.2174/0929867138049993032013.

13. Sasaki Y., et alComplementary and Alternative Medicine for Breast Cancer Patients: An Overview of Systematic Reviews. Yakugaku Zasshi. 139:1027–1046. 10.1248/yakushi.18-002152019.

14. Keinan-Boker L., van Der Schouw Y.T., Grobbee D.E., Peeters P.H.Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr. 79:282–288. 10.1093/ajcn/79.2.2822004.

15. Adlercreutz H.Phytoestrogens and breast cancer. J Steroid Biochem Mol Biol. 83:113–118. 10.1016/s0960-0760(02)00273-x2002.

16. Choi Y.K., et alSH003 suppresses breast cancer growth by accumulating p62 in autolysosomes. Oncotarget. 8:88386–88400. 10.18632/oncotarget.113932017.

17. Choi E.K., et alSH003 selectively induces p73dependent apoptosis in triplenegative breast cancer cells. Mol Med Rep. 14:3955–3960. 10.3892/mmr.2016.57222016.

18. Woo S.M., et alSynergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer. Phytother Res. 30:1817–1823. 10.1002/ptr.56872016.

19. Choi Y.J., et alSH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer. Biomed Res Int. 2022:364790010.1155/2022/36479002022.

20. Yu H., et alOptimizing combinations of flavonoids deriving from astragali radix in activating the regulatory element of erythropoietin by a feedback system control scheme. Evid Based Complement Alternat Med. 2013:54143610.1155/2013/5414362013.

21. McGrowder D.A., et alMedicinal Herbs Used in Traditional Management of Breast Cancer: Mechanisms of Action. Medicines (Basel). 7:10.3390/medicines70800472020.

22. Hsieh C.J., Hsu Y.L., Huang Y.F., Tsai E.M.Molecular Mechanisms of Anticancer Effects of Phytoestrogens in Breast Cancer. Curr Protein Pept Sci. 19:323–332. 10.2174/13892037186661701111212552018.

23. Tanwar A.K., Dhiman N., Kumar A., Jaitak V.Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach. Eur J Med Chem. 213:11303710.1016/j.ejmech.2020.1130372021.

24. Micek A., et alDietary phytoestrogens and biomarkers of their intake in relation to cancer survival and recurrence: a comprehensive systematic review with meta-analysis. Nutr Rev. 79:42–65. 10.1093/nutrit/nuaa0432021.

25. Chen J., Zhang X., Wang Y., Ye Y., Huang Z.Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERalpha. Mol Carcinog. 57:817–830. 10.1002/mc.225312018.